Hericium erinaceus fruiting body presented as a neutral botanical specimen. Hericium erinaceus fruiting body presented as a neutral botanical specimen.
REVESYN SCIENCE · INGREDIENT EVIDENCE · UPDATED SEPTEMBER 16, 2026

Lion’s Mane: Forms, Cognitive Research, and Evidence Limitations

Lion's Mane is the common name for Hericium erinaceus, an edible fungus studied in small human trials of cognition and mood. “Lion's Mane,” however, can describe very different materials: fruiting body, mycelium, powder, extract, and preparations standardized to different constituents.

The human evidence is early and mixed. This review keeps the study population, test material, dose, duration, and measured outcome attached to every finding.

EXPLORE THE SCIENCE LIBRARY OUR EVIDENCE METHODOLOGY

The quick read

  • Decorative species identity icon.
    Identity comes before a benefit claim

    Species, fungal material, growth substrate, processing, extraction, carrier, and assay can change what a preparation contains. A trial on one characterized material does not validate every product called Lion's Mane.

  • Decorative fungal material icon.
    Human cognitive findings are preliminary

    Small trials have reported selected positive results, null results, and borderline findings. A 2024 review of mushroom research found mixed results across ten human intervention studies, most of which evaluated Lion's Mane [3].

  • Decorative cognitive task icon.
    Nerve-growth language outruns the evidence

    Laboratory research on nerve growth factor and neuronal models helps generate hypotheses. It does not show that an oral supplement regenerates nerves, grows brain cells, prevents dementia, or produces clinically meaningful focus in humans.

IDENTITY & MATERIAL

Species and fungal anatomy matter

The scientific name most commonly associated with Lion's Mane is Hericium erinaceus. A complete ingredient description should still document how the species was authenticated and which fungal material was used.

Open the Science glossary

Three descriptions that must stay separate

  • Decorative species identity icon.
    Fruiting body

    The fruiting body is the visible reproductive structure commonly recognized as the mushroom. It can be dried and milled into powder or processed into an extract.

  • Decorative fungal material icon.
    Mycelium

    Mycelium is the network of fungal filaments that grows through a substrate. A mycelial ingredient may be separated from its growth medium or may retain material from that medium. The label and specification need to make that distinction clear.

  • Decorative cognitive task icon.
    Growth substrate

    Grain, wood-derived material, or another substrate can affect the composition of a cultivated fungal material. “Mycelium” alone does not reveal how much residual substrate is present.

    These are material descriptions, not quality grades. A fruiting body is not automatically effective, and a mycelial preparation is not automatically equivalent to another. The NIH Office of Dietary Supplements emphasizes that reproducible natural-product research requires authenticated, sufficiently characterized preparations [1].

PREPARATION CHANGES TRANSFERABILITY

Powder, extract, and ratio are not interchangeable

A ratio does not tell the reader how much beta-glucan, hericenone, erinacine, or another constituent is present. It also does not make one gram of extract clinically equivalent to ten grams of mushroom powder.

Two studies can use the same daily gram amount and still test materially different interventions. Conversely, two different gram amounts cannot be compared by ratio arithmetic alone.

What it can mean: Dried fungal material milled without a selective extraction step

What is still needed: Species, material, substrate boundary, identity method, moisture, serving amount

What it can mean: Material processed with water, alcohol, or another solvent to concentrate or separate constituents

What is still needed: Starting material, solvent, extraction conditions, yield, carrier, residual-solvent controls

What it can mean: More than one extraction step or solvent system

What is still needed: Exact process and the composition of the final material

What it can mean: Usually a relationship between starting material and extract output

What is still needed: Whether it is an input ratio or native-extract ratio, actual yield, carrier, and measured constituents

What it can mean: Prepared to meet a defined marker or constituent range

What is still needed: Which marker, assay method, specification, lot result, and evidence linking that marker to the outcome
CHARACTERIZATION, NOT EFFICACY

Constituents help characterize a material; they do not prove an outcome

Lion's Mane materials contain mixtures that can include polysaccharides, proteins, sterols, phenolic compounds, and small secondary metabolites. Research often highlights three groups:

Three constituent groups often discussed

  • Beta-glucans

    Beta-glucans are a broad class of polysaccharides found in fungal cell walls. A validated beta-glucan assay can contribute to composition testing, but the result is not, by itself, proof of species, purity, cognitive efficacy, or a clinically relevant dose.

  • Hericenones

    Hericenones have been isolated mainly in research on fruiting bodies. Their presence and amount depend on the exact material and method; a generic fruiting-body statement does not verify them.

  • Erinacines

    Erinacines are cyathane diterpenoids studied mainly in particular mycelial preparations. Evidence from an erinacine A-enriched mycelium cannot be transferred to an uncharacterized powder or fruiting-body extract [2,9].

    Chemical markers are useful when identity, method performance, specification, and lot results are known. They are not stand-alone “potency scores,” and a higher number is not automatically a better human outcome.

HUMAN OUTCOMES

What human evidence shows

The trials below do not test one interchangeable Lion's Mane intervention.

Each study card keeps the tested material, population, duration, finding, and reading boundary together.

Population and intervention: 30 Japanese adults aged 50–80 with mild cognitive impairment; about 3 g/day of H. erinaceus dry powder for 16 weeks

Main finding: Scores on one cognitive scale were higher than placebo at weeks 8, 12, and 16; scores declined four weeks after stopping

Reading boundary: Very small, diagnosis-specific trial; one scale; company mushroom-laboratory affiliation; no healthy-adult focus conclusion

Population and intervention: 31 adults over age 50; fruiting-body supplement for 12 weeks

Main finding: MMSE changed significantly; two other cognitive tests did not show the same result

Reading boundary: Small trial, multiple endpoints, limited material detail in the abstract; not dementia-prevention evidence

Population and intervention: 41 healthy adults aged 18–45; 1.8 g/day for 28 days

Main finding: Faster performance on one Stroop measure after an acute dose; chronic subjective-stress result was a trend at p=0.051

Reading boundary: Pilot study with null and limited negative findings; product was supplied by a mushroom company

Population and intervention: 24 college-age adults; 10 g/day in muffins for four weeks

Main finding: No significant effect on the measured cognition or metabolic-flexibility outcomes

Reading boundary: Single-blind, small study; useful direct null result

Population and intervention: 18 healthy adults aged 18–35; single 3 g dose of a 10:1 fruiting-body extract

Main finding: No significant effect on composite global cognition or mood; one individual pegboard task improved

Reading boundary: Acute, very small crossover study; individual-task signal after null composite; commercial affiliations disclosed
INTERPRETATION

The overall pattern is not a general cognitive claim

The 2024 systematic review identified 34 human mushroom studies: 24 observational studies and 10 interventions. Intervention findings were mixed, and the authors called for larger studies with sensitive, standardized testing [3]. The review covered more than Lion's Mane and received an unrestricted Mushroom Council grant, so it is a useful map rather than product-specific proof.

A 49-week pilot trial evaluated a specifically erinacine A-enriched mycelial preparation in people with mild Alzheimer's disease [9]. It cannot establish prevention, treatment, or a benefit in healthy adults, and it cannot be transferred to a different Lion's Mane material. Several authors were affiliated with the company that produced the preparation.

ENDPOINTS ARE NOT INTERCHANGEABLE

A cognitive test is not “brain performance”

Human cognitive research uses tasks designed to measure particular domains under controlled conditions. Examples include response inhibition, processing speed, working memory, visual retention, verbal learning, psychomotor skill, and global screening scores.

Those outcomes are not interchangeable:

  • a faster response on one Stroop measure does not establish better memory or everyday focus;
  • a screening score in an older clinical population does not predict performance in a healthy young adult;
  • an individual positive test after a null composite can be a hypothesis-generating signal, especially when many outcomes were measured;
  • a statistically significant difference may still be too small or too narrow to be noticeable in daily life;
  • a short study cannot establish persistence after use stops.

Confidence increases when a prespecified primary outcome improves, related measures point in the same direction, the effect is clinically meaningful, and independent studies using comparable materials reproduce it.

Read our evidence methodology

PRECLINICAL BOUNDARY

What NGF research can and cannot say

Nerve growth factor, or NGF, is a signaling protein involved in the development and maintenance of certain neurons. Lion's Mane constituents have been studied in cell systems and animals for effects related to NGF, neurite outgrowth, neuroinflammation, and neurogenesis.

This research is preclinical. It can support a mechanism hypothesis, but it does not show that swallowing an unspecified Lion's Mane product:

  • delivers the tested constituent to the same cells at the experimental concentration;
  • raises NGF in a relevant human tissue;
  • regenerates damaged nerves or brain cells;
  • improves a meaningful cognitive outcome.
  • prevents a neurodegenerative disease.

Explore cognitive-function research

SAFETY & UNCERTAINTY

Safety, uncertainty, and use

Small and short studies cannot establish uncommon or long-term risk. Open each item for the observed record and the remaining uncertainty.

Small and short studies have reported gastrointestinal symptoms and occasional rash or hypersensitivity, but they cannot establish uncommon or long-term risks.

NIH LiverTox reports that Lion’s Mane has not been linked to clinically apparent liver injury in the evidence it reviewed, while emphasizing limited human safety experience. This is not proof that every product or person is risk-free.

Lion's Mane is a fungus. Anyone with a known mushroom allergy should avoid use unless a qualified clinician advises otherwise. Stop use and seek urgent help for signs of a serious allergic reaction, such as difficulty breathing or swelling of the face or throat.

Long-term safety, reproductive safety, effects in children, and interactions with medications are not well established. Extraction, contamination, adulteration, residual substrate, co-ingredients, and dose can alter risk.

Ask a healthcare professional before use if you are pregnant or breastfeeding, take prescription medication, have a medical condition, have a mushroom allergy, or have a procedure planned. Do not use Lion's Mane to replace diagnosis, treatment, sleep, nutrition, or prescribed care.

Follow the final product label only after product identity and directions are verified. Stop use and seek advice if an adverse reaction occurs.

Read Safety & Transparency
KEEP THE BOUNDARIES VISIBLE

What the evidence does not establish

Current evidence does not establish that Lion's Mane:

  • regenerates nerves, neurons, or brain cells in humans;
  • causes proven human neurogenesis;
  • prevents or treats dementia, Alzheimer's disease, depression, anxiety, ADHD, or another condition;
  • produces clinically proven focus, memory, or mental clarity in healthy adults;
  • works the same as fruiting body, mycelium, powder, or extract;
  • is more effective because an extract ratio or beta-glucan value is higher;
  • has an established optimal dose for cognition;
  • slows brain aging or extends healthspan or lifespan;
  • works synergistically with NMN or another ingredient;
  • makes a finished REVESYN product clinically tested unless that product itself was studied.

Traditional use, fungal chemistry, cell experiments, animal behavior, one cognitive task, and a replicated human outcome are different evidence levels.

PRODUCT RELEVANCE

Ingredient evidence is not finished-product evidence

REVESYN Lion’s Mane Mushroom is labeled as 1,000 mg of Hericium erinaceus fruiting body and mycelium powder per two-capsule serving, with 40% polysaccharides (400 mg). Those label facts do not make it equivalent to a fruiting-body-only preparation, a 10:1 extract, or an erinacine A-enriched mycelial material used in a study. The 40% polysaccharides statement is not a beta-glucan declaration and does not establish cognitive efficacy.

None of the cited trials tested the finished REVESYN product. They therefore do not establish a clinical outcome, an optimal dose, or a study-level effect for this product. Product and lot documentation can answer defined identity and quality questions; it does not convert ingredient research into finished-product evidence.

The available Supliful records are bounded historical lot documents. This page does not claim a current-lot match, every-batch verification, product hericenones or erinacines, or finished-product clinical testing.

VIEW REVESYN LION’S MANE TESTING & VERIFICATION

Related product

REVESYN Lion’s Mane Mushroom bottle, 60 capsules.

Lion's Mane Mushroom

$44.99
$44.99
REVIEW RECORD

How to read this review

Randomized human trials and transparent descriptions of the tested material carry the most weight here. Cell and animal studies can explain a hypothesis; they do not establish a human cognitive outcome.

Evidence search through August 23, 2026. NIH ODS, LiverTox, FDA, and FTC pages rechecked September 16, 2026.

Educational information only; not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent disease.

READ OUR EVIDENCE METHODOLOGY RETURN TO SCIENCE

Continue through the evidence library

HUMAN STUDIES & OFFICIAL GUIDANCE

Selected references

The references below preserve the tested material, population, outcome, safety, and regulatory boundaries used on this page.

1. NIH Office of Dietary Supplements. The Importance of Natural Product Characterization and Integrity for Dietary Supplement Research. Current official page accessed September 16, 2026. https://ods.od.nih.gov/Funding/SupplementCharacterization.aspx

2. Friedman M. Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion's Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds. Journal of Agricultural and Food Chemistry. 2015;63(32):7108–7123. DOI 10.1021/acs.jafc.5b02914. PMID 26244378. https://pubmed.ncbi.nlm.nih.gov/26244378/

3. Cha S, Bell L, Shukitt-Hale B, Williams CM. A review of the effects of mushrooms on mood and neurocognitive health across the lifespan. Neuroscience & Biobehavioral Reviews. 2024;158:105548. DOI 10.1016/j.neubiorev.2024.105548. PMID 38246232. https://pubmed.ncbi.nlm.nih.gov/38246232/

4. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research. 2009;23(3):367–372. DOI 10.1002/ptr.2634. PMID 18844328. https://pubmed.ncbi.nlm.nih.gov/18844328/

5. Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomedical Research. 2019;40(4):125–131. DOI 10.2220/biomedres.40.125. PMID 31413233. https://pubmed.ncbi.nlm.nih.gov/31413233/

6. Docherty S, Doughty FL, Smith EF. The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study. Nutrients. 2023;15(22):4842. DOI 10.3390/nu15224842. PMID 38004235. https://pubmed.ncbi.nlm.nih.gov/38004235/

7. Grozier CD, Alves VA, Killen LG, Simpson JD, O'Neal EK, Waldman HS. Four Weeks of Hericium erinaceus Supplementation Does Not Impact Markers of Metabolic Flexibility or Cognition. International Journal of Exercise Science. 2022;15(2):1366–1380. DOI 10.70252/XZKO8571. PMID 36582308. https://pubmed.ncbi.nlm.nih.gov/36582308/

8. Surendran G, et al. Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Frontiers in Nutrition. 2025;12:1405796. DOI 10.3389/fnut.2025.1405796. PMID 40276537. https://pubmed.ncbi.nlm.nih.gov/40276537/

9. Li IC, et al. Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Frontiers in Aging Neuroscience. 2020;12:155. DOI 10.3389/fnagi.2020.00155. PMID 32581767. https://pubmed.ncbi.nlm.nih.gov/32581767/

10. National Institute of Diabetes and Digestive and Kidney Diseases. Lion's Mane. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Updated January 5, 2024. NCBI Bookshelf. PMID 38289992. https://www.ncbi.nlm.nih.gov/books/NBK599740/

11. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Annals of Internal Medicine. 2006;144(5):364–367. DOI 10.7326/0003-4819-144-5-200603070-00013. PMID 16520478. https://pubmed.ncbi.nlm.nih.gov/16520478/

12. U.S. Federal Trade Commission. Health Products Compliance Guidance. 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance

13. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements. Current official page accessed September 16, 2026. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements